{"id":936520,"date":"2026-02-12T08:22:36","date_gmt":"2026-02-12T13:22:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/heartflow-expands-gamefilm-registry-to-nba-and-nhl-alumni-precisely-measuring-heart-disease-risk-in-former-professional-athletes\/"},"modified":"2026-02-12T08:22:36","modified_gmt":"2026-02-12T13:22:36","slug":"heartflow-expands-gamefilm-registry-to-nba-and-nhl-alumni-precisely-measuring-heart-disease-risk-in-former-professional-athletes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/heartflow-expands-gamefilm-registry-to-nba-and-nhl-alumni-precisely-measuring-heart-disease-risk-in-former-professional-athletes\/","title":{"rendered":"Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes"},"content":{"rendered":"

\nNBA legend Muggsy Bogues joins effort to detect and manage coronary artery disease in retired players using AI-powered Heartflow Analysis
\n<\/h2>\n
\n

MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc.<\/u><\/a> (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced a significant expansion of its groundbreaking GAMEFILM Registry<\/u><\/a>. Building on a successful initial phase enrolling retired National Football League (NFL) athletes, the study will now extend to include former players from the National Basketball Association (NBA) and the National Hockey League (NHL), broadening Heartflow\u2019s initiative to protect the heart health of professional athletes across major sports. Retired NBA star Muggsy Bogues was one of the first former professional basketball players to join the GAMEFILM Registry and receive a CAD assessment with Heartflow\u2019s AI-driven technology.<\/p>\n

“My 14-year career as a professional athlete taught me the importance of staying on top of your health, especially heart health. I joined Heartflow\u2019s GAMEFILM Registry as soon as I heard about it because I\u2019ve lost too many friends to cardiovascular disease,” said former NBA point guard Muggsy Bogues. “Many of us push our bodies to the limits, and sometimes the signs of underlying issues can be overlooked. Heartflow Analysis offers an easy way to get a precise picture of what’s going on inside, without invasive procedures. I’m excited to see this technology benefit more athletes, giving them and their doctors a powerful tool for proactive heart care.”<\/p>\n

Heart disease is the leading cause of death in the United States and worldwide. It is known as the \u201csilent killer\u201d because it can progress for years without obvious signs or symptoms. For professional athletes who place immense, continuous demands on their cardiovascular systems, underlying heart issues can be easily masked. Heartflow Plaque Analysis<\/u><\/a> provides a thorough understanding of coronary plaque burden, which is essential for physicians to identify high-risk patients early and enable timely, preventative interventions. Four out of five heart attacks and strokes are preventable with lifestyle and nutrition changes if patients at high risk are identified early.1<\/sup><\/p>\n

The GAMEFILM Registry has already enrolled over 140 retired athletes from the NFL, NBA, and NHL. The study, currently active at 15 sites across the United States, aims to enroll up to 300 former players to better understand the prevalence, risk factors, severity, and treatment protocols for cardiovascular disease in this population. To do so, the registry addresses how advanced coronary computed tomography angiography (CCTA) imaging and AI-powered insights from Heartflow\u2019s first-of-its-kind non-invasive technology can identify different types of plaque in the coronary arteries \u2014 including those most likely to cause a cardiac event \u2014 and measure the effect on blood flow to the heart.2<\/sup><\/p>\n

\u201cExpanding our GAMEFILM Registry to include NBA and NHL athletes marks a pivotal moment for Heartflow, demonstrating our mission to revolutionize how heart disease is diagnosed, measured and managed,\u201d said John Farquhar, President and CEO of Heartflow, and an NFL alumnus. \u201cHeartflow\u2019s precision diagnostic capability will not only advance the health and safety of these athletes, but also generate invaluable insights that will benefit cardiovascular care more broadly.\u201d<\/p>\n

The expansion of the GAMEFILM registry will deepen understanding of how high-performance sports impact heart health over time. This data is expected to contribute significantly to the development of tailored screening protocols, preventative strategies, and personalized treatment plans.<\/p>\n

\u201cCardiovascular disease in former professional athletes is a paramount concern, but there\u2019s much we still don\u2019t understand about the disease in this population,\u201d said Jeffrey L. Boone, M.D., GAMEFILM Registry Primary Investigator and Founder and Medical Director of the Boone Heart Institute. \u201cWe\u2019ve seen the invaluable insights gained from our work with NFL alumni, identifying risks and guiding interventions. Bringing this same proactive, precision cardiovascular care to basketball and hockey players, who are also at unique risk due to the physical intensity of their sports, is a vital step in ensuring their long-term health.\u201d<\/p>\n

Heartflow is actively collaborating with organizations supporting former professional athletes to facilitate enrollment and to integrate the GAMEFILM Registry\u2019s insights into existing health and wellness programs. This initiative underscores Heartflow’s dedication to managing heart disease through partnering with physicians to generate robust, high-quality clinical evidence. To learn more and enroll in the GAMEFILM Registry, visit heartflow.com\/GAMEFILM<\/u><\/a>.<\/p>\n

\n About Heartflow\u2019s Technology and Research<\/strong>
\n
Heartflow\u2019s technology is redefining precision cardiovascular care through clinically-proven AI and the world\u2019s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC\/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide.3<\/sup> Key benefits include:<\/p>\n